|
A Journey from Blood Cells to Genes and Back
|
Aug 2023
|
Annual Review of Genomics and Human Genetics
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria
|
Aug 2023
|
Haematologica
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study
|
Jul 2023
|
American Journal of Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
|
Jul 2023
|
Lancet
|
myelodysplastic syndromes (MDS)
|
|
Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes?
|
Jul 2023
|
Lancet
|
myelodysplastic syndromes (MDS)
|
|
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care
|
Jul 2023
|
Transplantation and Cellular Therapy
|
myelodysplastic syndromes (MDS)
|
|
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
|
Jul 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study
|
Jul 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria
|
Jul 2023
|
Clinical and Experimental Medicine
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress
|
Jul 2023
|
Expert Review of Anticancer Therapies
|
myelodysplastic syndromes (MDS)
|
